| Autor: |
Egan K; Infectious Disease Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA, USA., Hook LM; Infectious Disease Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA, USA., Naughton A; Infectious Disease Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA, USA., Friedman HM; Infectious Disease Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA, USA., Awasthi S; Infectious Disease Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA, USA. |
| Abstrakt: |
A vaccine to prevent genital herpes is an unmet public health need. We previously reported that a trivalent vaccine containing herpes simplex virus type 2 (HSV-2) glycoproteins C, D, and E (gC2, gD2, gE2) produced in baculovirus and administered with CpG/alum as adjuvants blocks immune evasion mediated by gC2 and gE2 and virus entry by gD2. The vaccine protected guinea pigs against HSV-2 vaginal infection. We evaluated whether the HSV-2 vaccine cross-protects against HSV-1 because many first-time genital herpes infections are now caused by HSV-1. Guinea pigs were mock immunized or immunized with the trivalent vaccine and challenged intravaginally with a different HSV-1 isolate in two experiments. Guinea pigs immunized with the trivalent vaccine developed genital lesions on fewer days than the mock group: 2/477 (0.4%) days compared to 15/424 (3.5%) in experiment one, and 0/135 days compared to 17/135 (12.6%) in experiment two (both P < .001). No animal in the trivalent group had HSV-2 DNA detected in vaginal secretions: 0/180 days for trivalent compared to 4/160 (2.5%) for mock ( P < .05) in experiment one, and 0/65 days for trivalent compared to 4/65 (6%) for mock in experiment two. Therefore, a vaccine designed to prevent HSV-2 also protects against HSV-1 genital infection. |
